Home>Topics>Stocks>Teva Pharmaceutical Industries

Teva Pharmaceutical Industries TEVA

  1. All
  2. Commentary
  3. Stock Reports
  4. Video Reports
  5. Fund Reports
  6. ETF Reports
  7. Headlines
    1. Momenta Shifts Operations on Generic Copaxone Approval Delay

      Commentary

      Fri, 1 Aug 2014

      before a Supreme Court decision seems doubtful. Additionally, Teva reported a 19% decline in Copaxone sales this quarter, which ..... competitive landscape of the multiple sclerosis market. Additionally, Teva has now shifted nearly 50% of its patient base to the new three

    2. Teva Pharmaceutical Industries' ( TEVA ) CEO Erez Vigodman on Q2 2014 Results - Earnings Call Transcript

      Headlines

      Thu, 31 Jul 2014

      Teva Pharmaceutical Industries Limited (NYSE: TEVA ) Q2 2014 Earnings Conference Call July 31, 2014 8:00 am ET Executives Kevin C. Mannix - VP, Head of Investor Relations Erez Vigodman - President and CEO Eyal Desheh - Group EVP and CFO Richard

    3. UPDATE 1- Teva Pharm raises full-year profit forecast after solid second quarter

      Headlines

      Thu, 31 Jul 2014

      * Now sees 2014 EPS $4.50-$4.80 with Copaxone competition

    4. Teva Pharm shareholder optimistic of change despite losing vote

      Headlines

      Thu, 31 Jul 2014

      JERUSALEM, July 31 (Reuters) - Israeli industrialist Benny Landa said his campaign to improve corporate governance at Teva Pharmaceutical Industries was delivering results, despite losing a shareholder vote at the world's largest generic drugmaker.

    5. BRIEF- Teva 2014 revenue outlook

      Headlines

      Thu, 31 Jul 2014

      July 31 (Reuters) - Teva Pharmaceutical Industries Ltd said:

    6. More on Teva Q2 results

      Headlines

      Thu, 31 Jul 2014

      Teva Pharmaceutical Industries (NYSE: TEVA ) Q2 results : Total Revenues: $5,045M (+2.5%), Generic Medicine: $2,515M (+4.3%), Specialty Medicine: $2,027M (-1.2%); Operating Income: $1,094M (+14.8

    7. Teva Pharm Q2 profit, revenue up on generic launches

      Headlines

      Thu, 31 Jul 2014

      TEL AVIV, July 31 (Reuters) - Teva Pharmaceutical Industries reported on Thursday higher quarterly earnings that beat analysts' estimates by one cent due in part to the launch of several generic products in the United States.

    8. Teva Pharmaceutical beats by $0.02, misses on revenue

      Headlines

      Thu, 31 Jul 2014

      Teva Pharmaceutical (NYSE: TEVA ): Q2 EPS of $1.23 beats by $0.02 . Revenue of $5.04B (+2.4% Y/Y) misses by $40M . Press Release Post your comment!

    9. Teva says shareholders favor management as shakeup fizzles

      Headlines

      Wed, 30 Jul 2014

      July 30 (Reuters) - Israeli drugmaker Teva Pharmaceuticals Industries said on Wednesday it turned back efforts by Israeli industrialist Benny Landa to shake up the company's board of directors, with shareholders approving all of the company's proposals and board nominations.

    10. Notable earnings before Thursday’s open

      Headlines

      Wed, 30 Jul 2014

      PNW , PPL , PRFT , PWR , Q , RFP , RYL , SBH , SC , SCG , SFY , SHOO , SNAK , SNMX , STC , STRA , STRZA , SUP , SWC , TE , TEVA , TKR , TRP , TWC , UAN , UPL , USAK , VG , VICL , VNTV , VRX , WLT , WWE , XEL , XOM , XRAY Post your comment!

    « Prev12345Next »
    Content Partners